Stock NCNA NUCANA PLC
Add to a list
To use this feature you must be a member
Log inSign up

Company NuCana plc

Equities

NCNA

US67022C2052

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-17 pm EDT 		5-day change 1st Jan Change
3.97 USD +1.79% Intraday chart for NuCana plc -32.88% -46.32%
Apr. 17 European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
Apr. 16 NuCana Completes ADS to Ordinary Share Ratio Change MT

Business Summary

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.

Number of employees: 27

Managers

Managers TitleAgeSince
Hugh Griffith FOU
 Founder 56 97-01-27
Donald Munoz DFI
 Director of Finance/CFO 56 15-09-30
Michelle Myers CTO
 Chief Tech/Sci/R&D Officer - -
Elisabeth Oelmann CTO
 Chief Tech/Sci/R&D Officer - 20-08-31
Theresa Margaret Bruce CTO
 Chief Tech/Sci/R&D Officer 60 -
Jeffrey Bloss CTO
 Chief Tech/Sci/R&D Officer 68 21-08-09
John-Paul Gallivan PRN
 Corporate Officer/Principal - -
Martin Alexander Quinn SEC
 Corporate Secretary - 17-08-28
Stuart Grant LAW
 General Counsel - 18-08-31

Members of the board

Members of the board TitleAgeSince
Hugh Griffith FOU
 Founder 56 97-01-27
Andrew Kay CHM
 Chairman 69 20-12-20
Adam George BRD
 Director/Board Member 54 18-04-03
Martin Mellish BRD
 Director/Board Member 66 09-12-13
Bali Muralidhar BRD
 Director/Board Member 44 20-10-12
Elliott Levy BRD
 Director/Board Member 64 21-10-31
Cyrille Leperlier BRD
 Director/Board Member 70 18-04-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 52,860,000 51,658,179 ( 97.73 %) 0 97.73 %

Shareholders

NameEquities%Valuation
Baillie Gifford & Co.
7.012 %
3,659,030 7.012 % 951 348 $
Abingworth LLP
6.388 %
3,333,333 6.388 % 866 667 $
Woodford Investment Management Ltd.
4.414 %
2,303,000 4.414 % 598 780 $
Sofinnova Investments, Inc.
4.230 %
2,207,410 4.230 % 573 927 $
Acadian Asset Management LLC
1.132 %
590,651 1.132 % 153 569 $
Renaissance Technologies LLC
0.9920 %
517,646 0.9920 % 134 588 $
HRK LUNIS AG
0.4216 %
220,000 0.4216 % 57 200 $
Infinity Q Capital Management LLC
0.3114 %
162,478 0.3114 % 42 244 $
Citadel Securities GP LLC
0.2800 %
146,083 0.2800 % 37 982 $
Two Sigma Securities LLC
0.1111 %
57,988 0.1111 % 15 077 $
NameEquities%Valuation
Sofinnova Partners SAS
15.65 %
4,978,993 15.65 % 1 M $
Sofinnova Investments, Inc.
13.07 %
4,157,244 13.07 % 1 M $
Hugh Griffith
3.977 %
1,265,026 3.977 % 328 907 $
Donald Munoz
0.4865 %
154,760 0.4865 % 40 238 $
James Healy
0.2555 %
81,262 0.2555 % 21 128 $
Martin Mellish
0.0879 %
27,952 0.0879 % 7 268 $
Elliott Levy
0.0147 %
4,688 0.0147 % 1 219 $
Bali Muralidhar
0.001698 %
540 0.001698 % 140 $
Jeffrey Bloss
0.000314 %
100 0.000314 % 26 $
Adam George
0.000000 %
0 0.000000 % - $

Company contact information

NuCana Plc

3 Lochside Way

EH12 9DT, Edinburgh

+44 13 1357 1111

http://www.nucana.com
address NuCana plc(NCNA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.97 USD
Average target price
119.8 USD
Spread / Average Target
+2,918.47%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
NUCANA PLC Stock NuCana plc
-46.32% 8.31M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.39% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.61% 96.84B
ARGENX SE Stock argenx SE
-1.02% 21.48B
BIONTECH SE Stock BioNTech SE
-18.14% 20.82B
GENMAB A/S Stock Genmab A/S
-6.87% 18.6B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.70% 16.81B
BEIGENE, LTD. Stock BeiGene, Ltd.
-26.89% 13.78B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.12% 13.4B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+22.25% 11.06B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NCNA Stock
  4. Company NuCana plc